propafenone has been researched along with Atrial Flutter in 77 studies
Propafenone: An antiarrhythmia agent that is particularly effective in ventricular arrhythmias. It also has weak beta-blocking activity.
propafenone : An aromatic ketone that is 3-(propylamino)propane-1,2-diol in which the hydrogen of the primary hydroxy group is replaced by a 2-(3-phenylpropanoyl)phenyl group. It is a class 1C antiarrhythmic drug with local anesthetic effects, and is used as the hydrochloride salt in the management of supraventricular and ventricular arrhythmias.
Atrial Flutter: Rapid, irregular atrial contractions caused by a block of electrical impulse conduction in the right atrium and a reentrant wave front traveling up the inter-atrial septum and down the right atrial free wall or vice versa. Unlike ATRIAL FIBRILLATION which is caused by abnormal impulse generation, typical atrial flutter is caused by abnormal impulse conduction. As in atrial fibrillation, patients with atrial flutter cannot effectively pump blood into the lower chambers of the heart (HEART VENTRICLES).
| Excerpt | Relevance | Reference |
|---|---|---|
| "To investigate the efficacy and safety of intravenous ibutilide for conversion of atrial fibrillation (AF) and flutter (AFL) to sinus rhythm." | 9.17 | [Efficacy and safety of ibutilide for conversion of atrial fibrillation/flutter]. ( Ma, C; Xiang, M; Yang, Y; Yu, Z; Zhang, S, 2013) |
| "We evaluated the safety and efficacy of ibutilide when added to propafenone in treating both paroxysmal and chronic atrial fibrillation (AF) and atrial flutter (AFL)." | 9.11 | Ibutilide added to propafenone for the conversion of atrial fibrillation and atrial flutter. ( Chiladakis, JA; Kalogeropoulos, A; Manolis, AS; Patsouras, N, 2004) |
| "We sought to assess the efficacy and safety of ibutilide cardioversion for those with atrial fibrillation (AF) or atrial flutter (AFL) receiving long-term treatmentwith class IC agents." | 9.11 | Use of ibutilide in cardioversion of patients with atrial fibrillation or atrial flutter treated with class IC agents. ( Bonso, A; Glatter, KA; Hongo, RH; Raviele, A; Rossillo, A; Scheinman, MM; Themistoclakis, S; Yang, Y, 2004) |
| "To evaluate the efficacy and safety of intravenous ibutilide and propafenone for immediate treatment of atrial flutter." | 9.11 | Clinical comparison of ibutilide and propafenone for converting atrial flutter. ( Guo, JH; Sun, JL; Zhang, HC; Zhang, N; Zhang, P, 2005) |
| "To compare the efficacy and safety of ibutilide versus propafenone in immediate cardioversion of atrial fibrillation (AF) and atrial flutter (AFL) lasted less than 90 days." | 9.11 | [Immediate cardioversion of atrial fibrillation and atrial flutter lasting less than 90 days by ibutilide versus propafenone: a multicenter study]. ( Fang, Q; Ge, JB; Guo, JH; Guo, JX; Han, SM; Sun, YM; Wan, Z; Zhang, HC; Zheng, YA; Zhu, WQ, 2005) |
| "This multicentre, randomized, double-blind study, conducted in parallel groups, was designed to compare the efficacy and safety of cibenzoline (C) and oral propafenone (P) in the prevention of recurrent atrial arrhythmias (M) over a 6-month period." | 9.08 | [Cibenzoline versus propafenone by the oral route for preventing recurrence of atrial arrhythmia: multicenter, randomized, double-blind study]. ( Bleinc, D; Canler, A; Lardoux, H; Maison Blanche, P; Marchand, X; Péraudeau, P; Rouesnel, P; Scheck, F, 1996) |
| "Fifty patients with symptomatic type I atrial flutter in whom termination of the arrhythmia with transesophageal stimulation was unsuccessful were randomized to undergo a repeat procedure after intravenous propafenone (n = 25) or placebo (n = 25)." | 9.08 | Efficacy of intravenous propafenone in termination of atrial flutter by overdrive transesophageal pacing previously ineffective. ( Bertaglia, E; D'Este, D; Franceschi, M; Mantovan, R; Pascotto, P; Zanocco, A, 1997) |
| "The results suggest that propafenone produces a more prompt effect in converting patients from atrial fibrillation or flutter to normal sinus rhythm." | 9.08 | The efficacy and safety of intravenous propafenone versus intravenous amiodarone in the conversion of atrial fibrillation or flutter after cardiac surgery. ( Larbuisson, R; Stiels, B; Venneman, I, 1996) |
| "Safety and efficacy of propafenone and disopyramide for long-term maintenance of sinus rhythm after electrical cardioversion was studied in 56 patients with chronic atrial fibrillation (median arrhythmia duration, 5 months)." | 9.08 | Propafenone versus disopyramide for maintenance of sinus rhythm after electrical cardioversion of chronic atrial fibrillation: a randomized, double-blind study. PRODIS Study Group. ( Crijns, HJ; Gosselink, AT; Lie, KI, 1996) |
| "To assess the cardiac and extracardiac safety and efficacy of flecainide versus propafenone in patients suffering from episodes of paroxysmal atrial fibrillation (AF) or atrial flutter, 97 patients were enrolled in a randomized, open-label, long-term, parallel, comparative multicenter study." | 9.08 | Comparison of the safety and efficacy of flecainide versus propafenone in hospital out-patients with symptomatic paroxysmal atrial fibrillation/flutter. The Flecainide AF French Study Group. ( Aliot, E; Denjoy, I, 1996) |
| "The safety and efficacy of amiodarone and propafenone in converting atrial fibrillation or flutter after cardiac surgery were compared in a randomized double-blind trial." | 9.08 | Intravenous amiodarone vs propafenone for atrial fibrillation and flutter after cardiac operation. ( Cappiello, E; Di Biasi, P; Mangini, A; Paje, A; Santoli, C; Scrofani, R, 1995) |
| "Efficacy and safety of intravenous flecainide (2 mg/kg body weight in 10 minutes), verapamil (10 mg in 1 minute), and propafenone (2 mg/kg body weight in 10 minutes) were investigated in 90 consecutive patients with atrial fibrillation (AF) or flutter (AFL)." | 9.07 | Acute pharmacologic conversion of atrial fibrillation and flutter: the role of flecainide, propafenone, and verapamil. ( Kingma, JH; Suttorp, MJ, 1992) |
| "The efficacy of intravenous propafenone (2 mg/kg) was assessed in 83 consecutive patients: 68 with atrial fibrillation (AF) and 15 with atrial flutter lasting less than 15 days." | 9.06 | Effectiveness of intravenous propafenone for conversion of atrial fibrillation and flutter of recent onset. ( Bianconi, L; Boccadamo, R; Gentili, C; Pappalardo, A; Pistolese, M, 1989) |
| "This review summarizes the results of placebo-controlled trials of propafenone, a class IC antiarrhythmic drug, in patients with supraventricular tachycardia, atrial fibrillation (AF), and atrial flutter." | 8.80 | Placebo-controlled evaluations of propafenone for atrial tachyarrhythmias. ( Rae, AP, 1998) |
| "Our objective was to evaluate the efficacy and safety of intravenous (IV) sotalol in the treatment of incessant tachyarrhythmias in children with normal cardiac function." | 7.85 | Efficacy of Intravenous Sotalol for Treatment of Incessant Tachyarrhythmias in Children. ( Ge, H; Jiang, H; Li, X; Liu, H; Zhang, Y, 2017) |
| "We present two cases of proarrhythmia after propafenone treatment." | 7.74 | [Proarrhythmic effect of propafenone in patients with atrial fibrillation and atrial flutter]. ( Jastrzebski, M, 2008) |
| " The case history is reported of a patient with atrial flutter and atrial fibrillation who developed Brugada-like ECG changes when treated with propafenone." | 7.74 | Propafenone-induced Brugada-like ECG changes mistaken as acute myocardial infarction. ( Chutani, S; Grubb, B; Imran, N; Kanjwal, Y, 2008) |
| "The effectiveness and safety of ibutilide (IB) use in patients receiving amiodarone or propafenone for atrial flutter (AFL) and atrial fibrillation (AF) were compared to IB alone." | 7.73 | Efficacy and safety of ibutilide for cardioversion of atrial flutter and fibrillation in patients receiving amiodarone or propafenone. ( Fragakis, N; Katsaris, G; Kozirakis, M; Maligkos, G; Papadopoulos, N; Papanastasiou, S; Tsaritsaniotis, E, 2005) |
| "Among the 136 patients treated for atrial fibrillation with amiodarone (n = 96) or propafenone (n = 40), 15 (11%, mean age 65." | 7.70 | Persistent atrial flutter in patients treated for atrial fibrillation with amiodarone and propafenone: electrophysiologic characteristics, radiofrequency catheter ablation, and risk prediction. ( Chang, MS; Chen, SA; Chen, YJ; Chiang, CE; Ding, YA; Feng, AN; Lee, SH; Tai, CT; Yu, WC, 1999) |
| "We describe a case of 1:1 atrial flutter in a patient with coronary disease taking propafenone." | 7.70 | Atrial flutter with 1:1 atrioventricular conduction caused by propafenone. ( Adams, PC; el-Harari, MB, 1998) |
| "The effects of procainamide and propafenone on the composition of the excitable gap (EG) were studied in a canine model of atrial flutter (AFI) around the tricuspid valve." | 7.69 | Effects of procainamide and propafenone on the composition of the excitable gap in canine atrial reentry tachycardia. ( Derakhchan, K; Kus, T; Lambert, C; Pagé, P, 1994) |
| " In order to prevent/terminate fibrillation propafenone (Rytmonorm, 450-600 mg/day) was started, however this therapy resulted in permanent atrial flutter of 230-270/min mainly with 2:1 antrioventricular conduction." | 7.69 | [Persistent atrial flutter induced by propafenone (Rytmonorm)]. ( Fazekas, T; Kiss, J; Pap, I; Rudas, L, 1994) |
| "0 micrograms/kg, n = 8), a class III drug, on atrial flutter (AF) caused by reentry were compared with those of disopyramide (1." | 7.68 | Effects of pentisomide and E-4031 on canine atrial flutter due to reentry: a comparative study with disopyramide and propafenone. ( Inoue, H; Nozaki, A; Saihara, S; Sugimoto, T; Usui, M; Yamashita, T, 1991) |
| "The safety and efficacy of intravenous Propafenone, in the treatment of atrial fibrillation (a." | 7.67 | [Fibrillation and atrial flutter. Immediate control and conversion to sinus rhythm with intravenous propafenone]. ( Bianconi, L; Boccadamo, R; Broglia, R; Pappalardo, A; Pistolese, M, 1987) |
| "Sixty patients who had recurrent episodes of symptomatic atrial fibrillation or flutter, or both, and who had failed one to five prior drug trials were treated with open label oral propafenone hydrochloride." | 7.67 | Long-term oral propafenone therapy for suppression of refractory symptomatic atrial fibrillation and atrial flutter. ( Antman, EM; Beamer, AD; Cantillon, C; Friedman, PL; Goldman, L; McGowan, N, 1988) |
| "Forty-seven patients with chronic atrial fibrillation and (or) flutter in whom the clinical picture and the length of arrhythmia indicated that drug-mediated cardioversion should be tried were treated with a combination of lidoflazine and propafenon." | 7.66 | [Combined use of propafenon and lidoflazine in chronic atrial fibrillation and flutter (author's transl)]. ( Beck, OA; Hochrein, H, 1980) |
| "Oral propafenone was administered and within 6 hours no further arrhythmias or side effects were noted." | 5.30 | Atrial flutter in a pediatric patient in the immediate period after the Fontan procedure: control with oral propafenone. ( Herzberg, GZ; Rossi, AF, 1997) |
| " Dosage and serum levels of propafenone did not differ whether the patients were treated successfully or not." | 5.29 | Clinical experience with propafenone for cardiac arrhythmias in the young. ( Bourgeous, M; Heusch, A; Kramer, HH; Krogmann, ON; Rammos, S, 1994) |
| "Propafenone was less effective (mean effect 3." | 5.27 | European experience with the antiarrhythmic efficacy of propafenone for supraventricular and ventricular arrhythmias. ( Assayag, P; Coumel, P; Leclercq, JF, 1984) |
| "To investigate the efficacy and safety of intravenous ibutilide for conversion of atrial fibrillation (AF) and flutter (AFL) to sinus rhythm." | 5.17 | [Efficacy and safety of ibutilide for conversion of atrial fibrillation/flutter]. ( Ma, C; Xiang, M; Yang, Y; Yu, Z; Zhang, S, 2013) |
| "We evaluated the safety and efficacy of ibutilide when added to propafenone in treating both paroxysmal and chronic atrial fibrillation (AF) and atrial flutter (AFL)." | 5.11 | Ibutilide added to propafenone for the conversion of atrial fibrillation and atrial flutter. ( Chiladakis, JA; Kalogeropoulos, A; Manolis, AS; Patsouras, N, 2004) |
| "We sought to assess the efficacy and safety of ibutilide cardioversion for those with atrial fibrillation (AF) or atrial flutter (AFL) receiving long-term treatmentwith class IC agents." | 5.11 | Use of ibutilide in cardioversion of patients with atrial fibrillation or atrial flutter treated with class IC agents. ( Bonso, A; Glatter, KA; Hongo, RH; Raviele, A; Rossillo, A; Scheinman, MM; Themistoclakis, S; Yang, Y, 2004) |
| "To evaluate the efficacy and safety of intravenous ibutilide and propafenone for immediate treatment of atrial flutter." | 5.11 | Clinical comparison of ibutilide and propafenone for converting atrial flutter. ( Guo, JH; Sun, JL; Zhang, HC; Zhang, N; Zhang, P, 2005) |
| "To compare the efficacy and safety of ibutilide versus propafenone in immediate cardioversion of atrial fibrillation (AF) and atrial flutter (AFL) lasted less than 90 days." | 5.11 | [Immediate cardioversion of atrial fibrillation and atrial flutter lasting less than 90 days by ibutilide versus propafenone: a multicenter study]. ( Fang, Q; Ge, JB; Guo, JH; Guo, JX; Han, SM; Sun, YM; Wan, Z; Zhang, HC; Zheng, YA; Zhu, WQ, 2005) |
| "We conclude that the association of propafenone with long bursts gives the best result for interruption of new onset atrial flutter by transoesophageal pacing." | 5.09 | New onset atrial flutter termination by overdrive transoesophageal pacing: effects of different protocols of stimulation. ( Doni, F; Fiorentini, C; Manfredi, M; Piemonti, C; Rimondini, A; Staffiere, E; Todd, S, 2000) |
| "The safety and efficacy of amiodarone and propafenone in converting atrial fibrillation or flutter after cardiac surgery were compared in a randomized double-blind trial." | 5.08 | Intravenous amiodarone vs propafenone for atrial fibrillation and flutter after cardiac operation. ( Cappiello, E; Di Biasi, P; Mangini, A; Paje, A; Santoli, C; Scrofani, R, 1995) |
| "Safety and efficacy of propafenone and disopyramide for long-term maintenance of sinus rhythm after electrical cardioversion was studied in 56 patients with chronic atrial fibrillation (median arrhythmia duration, 5 months)." | 5.08 | Propafenone versus disopyramide for maintenance of sinus rhythm after electrical cardioversion of chronic atrial fibrillation: a randomized, double-blind study. PRODIS Study Group. ( Crijns, HJ; Gosselink, AT; Lie, KI, 1996) |
| "The results suggest that propafenone produces a more prompt effect in converting patients from atrial fibrillation or flutter to normal sinus rhythm." | 5.08 | The efficacy and safety of intravenous propafenone versus intravenous amiodarone in the conversion of atrial fibrillation or flutter after cardiac surgery. ( Larbuisson, R; Stiels, B; Venneman, I, 1996) |
| "This multicentre, randomized, double-blind study, conducted in parallel groups, was designed to compare the efficacy and safety of cibenzoline (C) and oral propafenone (P) in the prevention of recurrent atrial arrhythmias (M) over a 6-month period." | 5.08 | [Cibenzoline versus propafenone by the oral route for preventing recurrence of atrial arrhythmia: multicenter, randomized, double-blind study]. ( Bleinc, D; Canler, A; Lardoux, H; Maison Blanche, P; Marchand, X; Péraudeau, P; Rouesnel, P; Scheck, F, 1996) |
| "To assess the cardiac and extracardiac safety and efficacy of flecainide versus propafenone in patients suffering from episodes of paroxysmal atrial fibrillation (AF) or atrial flutter, 97 patients were enrolled in a randomized, open-label, long-term, parallel, comparative multicenter study." | 5.08 | Comparison of the safety and efficacy of flecainide versus propafenone in hospital out-patients with symptomatic paroxysmal atrial fibrillation/flutter. The Flecainide AF French Study Group. ( Aliot, E; Denjoy, I, 1996) |
| "Fifty patients with symptomatic type I atrial flutter in whom termination of the arrhythmia with transesophageal stimulation was unsuccessful were randomized to undergo a repeat procedure after intravenous propafenone (n = 25) or placebo (n = 25)." | 5.08 | Efficacy of intravenous propafenone in termination of atrial flutter by overdrive transesophageal pacing previously ineffective. ( Bertaglia, E; D'Este, D; Franceschi, M; Mantovan, R; Pascotto, P; Zanocco, A, 1997) |
| "Efficacy and safety of intravenous flecainide (2 mg/kg body weight in 10 minutes), verapamil (10 mg in 1 minute), and propafenone (2 mg/kg body weight in 10 minutes) were investigated in 90 consecutive patients with atrial fibrillation (AF) or flutter (AFL)." | 5.07 | Acute pharmacologic conversion of atrial fibrillation and flutter: the role of flecainide, propafenone, and verapamil. ( Kingma, JH; Suttorp, MJ, 1992) |
| "In a single-blind randomized study, the efficacy and safety of intravenous propafenone (2 mg/kg body weight per 10 min) versus flecainide (2 mg/kg per 10 min) were assessed in 50 patients with atrial fibrillation or flutter." | 5.06 | The value of class IC antiarrhythmic drugs for acute conversion of paroxysmal atrial fibrillation or flutter to sinus rhythm. ( Jessurun, ER; Kingma, JH; Lie, KI; Lie-A-Huen, L; Suttorp, MJ; van Hemel, NM, 1990) |
| "The efficacy of intravenous propafenone (2 mg/kg) was assessed in 83 consecutive patients: 68 with atrial fibrillation (AF) and 15 with atrial flutter lasting less than 15 days." | 5.06 | Effectiveness of intravenous propafenone for conversion of atrial fibrillation and flutter of recent onset. ( Bianconi, L; Boccadamo, R; Gentili, C; Pappalardo, A; Pistolese, M, 1989) |
| "This review summarizes the results of placebo-controlled trials of propafenone, a class IC antiarrhythmic drug, in patients with supraventricular tachycardia, atrial fibrillation (AF), and atrial flutter." | 4.80 | Placebo-controlled evaluations of propafenone for atrial tachyarrhythmias. ( Rae, AP, 1998) |
| " These antiarrhythmics, prescribed to prevent atrial fibrillation (3 patients) and atrial flutter (5 patients), were flecainide in 4 cases, propafenone in 2 cases and cibenzoline and hydroquinidine respectively associated with digitoxine and propranolol." | 4.79 | [Supraventricular tachycardia with wide QRS complexes during Vaughan-Williams class I anti-arrhythmic treatment. Diagnostic and therapeutic implications]. ( Aouate, P; Benassar, A; Fontaine, G; Frank, R; Jacquemin, M; Laborde, JP; Tageddine, R; Tonet, J; Turlure, A, 1995) |
| "The use of flecainide and propafenone for medical cardioversion of atrial fibrillation (AF) and atrial flutter/intra-atrial reentrant tachycardia (IART) is well-described in adults without congenital heart disease (CHD)." | 4.31 | Medical cardioversion of atrial fibrillation and flutter with class IC antiarrhythmic drugs in young patients with and without congenital heart disease. ( Alexander, ME; Bezzerides, VJ; DeWitt, ES; Dionne, A; Eberly, LM; Mah, DY; O'Leary, ET; Przybylski, R; Triedman, JK; Walsh, EP, 2023) |
| "Our objective was to evaluate the efficacy and safety of intravenous (IV) sotalol in the treatment of incessant tachyarrhythmias in children with normal cardiac function." | 3.85 | Efficacy of Intravenous Sotalol for Treatment of Incessant Tachyarrhythmias in Children. ( Ge, H; Jiang, H; Li, X; Liu, H; Zhang, Y, 2017) |
| "We present two cases of proarrhythmia after propafenone treatment." | 3.74 | [Proarrhythmic effect of propafenone in patients with atrial fibrillation and atrial flutter]. ( Jastrzebski, M, 2008) |
| " The case history is reported of a patient with atrial flutter and atrial fibrillation who developed Brugada-like ECG changes when treated with propafenone." | 3.74 | Propafenone-induced Brugada-like ECG changes mistaken as acute myocardial infarction. ( Chutani, S; Grubb, B; Imran, N; Kanjwal, Y, 2008) |
| "The antiarrhythmic efficacy of the novel ultrarapid delayed rectifier potassium current (IKur) blocker (2-isopropyl-5-methylcyclohexyl) diphenylphosphine oxide (DPO-1) was compared with efficacies of the standard class III rapidly activating component of delayed rectifier potassium current (IKr) blockers [+-N-[1'-(6-cyano-1,2,3,4-tetrahydro-2-napthalenyl)-3,4-dihydro-4-hydroxyspiro[2H-1-benzopyran-2,4'-piperidin]-6-yl] methanesulfonamide hydrochloride (MK499) and ibutilide and the class IC agent propafenone in a canine model of Y-shaped intracaval and right atrial free wall surgical lesions producing the substrate for reentrant atrial flutter." | 3.73 | In vivo antiarrhythmic and cardiac electrophysiologic effects of a novel diphenylphosphine oxide IKur blocker (2-isopropyl-5-methylcyclohexyl) diphenylphosphine oxide. ( Lynch, JJ; Regan, CP; Stump, GL; Wallace, AA, 2005) |
| "The effectiveness and safety of ibutilide (IB) use in patients receiving amiodarone or propafenone for atrial flutter (AFL) and atrial fibrillation (AF) were compared to IB alone." | 3.73 | Efficacy and safety of ibutilide for cardioversion of atrial flutter and fibrillation in patients receiving amiodarone or propafenone. ( Fragakis, N; Katsaris, G; Kozirakis, M; Maligkos, G; Papadopoulos, N; Papanastasiou, S; Tsaritsaniotis, E, 2005) |
| "A 74-year-old man with a structurally normal heart presented with typical atrial flutter, after treatment of atrial fibrillation with propafenone." | 3.72 | Typical counterclockwise atrial flutter occurring despite absence of the inferior vena cava. ( Gilkeson, RC; Varma, N; Waldo, AL, 2004) |
| "24 consecutive patients with atrial fibrillation (age 54 (12) years; 5 female, 19 male) developing atrial flutter while taking propafenone (n = 12) or flecainide (n = 12)." | 3.71 | Class IC antiarrhythmic drug induced atrial flutter: electrocardiographic and electrophysiological findings and their importance for long term outcome after right atrial isthmus ablation. ( Nabar, A; Rodriguez, LM; Timmermans, C; van Mechelen, R; Wellens, HJ, 2001) |
| "We describe a case of 1:1 atrial flutter in a patient with coronary disease taking propafenone." | 3.70 | Atrial flutter with 1:1 atrioventricular conduction caused by propafenone. ( Adams, PC; el-Harari, MB, 1998) |
| "Among the 136 patients treated for atrial fibrillation with amiodarone (n = 96) or propafenone (n = 40), 15 (11%, mean age 65." | 3.70 | Persistent atrial flutter in patients treated for atrial fibrillation with amiodarone and propafenone: electrophysiologic characteristics, radiofrequency catheter ablation, and risk prediction. ( Chang, MS; Chen, SA; Chen, YJ; Chiang, CE; Ding, YA; Feng, AN; Lee, SH; Tai, CT; Yu, WC, 1999) |
| "Ibutilide, with a unique increase in atrial refractoriness, was more effective in conversion of atrial flutter than were propafenone and amiodarone." | 3.70 | Electropharmacologic effects of class I and class III antiarrhythmia drugs on typical atrial flutter: insights into the mechanism of termination. ( Chang, MS; Chen, SA; Chen, YJ; Feng, AN; Tai, CT; Yu, WC, 1998) |
| "We assessed the safety and efficacy of intravenous propafenone in the treatment of atrial fibrillation and flutter of recent onset (1-10 days)." | 3.69 | [Efficacy of intravenous propafenone in the management of arterial flutter and fibrillation of recent onset]. ( Minutiello, L, 1994) |
| "The effects of procainamide and propafenone on the composition of the excitable gap (EG) were studied in a canine model of atrial flutter (AFI) around the tricuspid valve." | 3.69 | Effects of procainamide and propafenone on the composition of the excitable gap in canine atrial reentry tachycardia. ( Derakhchan, K; Kus, T; Lambert, C; Pagé, P, 1994) |
| " In order to prevent/terminate fibrillation propafenone (Rytmonorm, 450-600 mg/day) was started, however this therapy resulted in permanent atrial flutter of 230-270/min mainly with 2:1 antrioventricular conduction." | 3.69 | [Persistent atrial flutter induced by propafenone (Rytmonorm)]. ( Fazekas, T; Kiss, J; Pap, I; Rudas, L, 1994) |
| "0 micrograms/kg, n = 8), a class III drug, on atrial flutter (AF) caused by reentry were compared with those of disopyramide (1." | 3.68 | Effects of pentisomide and E-4031 on canine atrial flutter due to reentry: a comparative study with disopyramide and propafenone. ( Inoue, H; Nozaki, A; Saihara, S; Sugimoto, T; Usui, M; Yamashita, T, 1991) |
| " To determine the exact role played by these two electrophysiologic effects in the termination of reentry, the effects of disopyramide, flecainide, propafenone and E-4031, a new class III drug, were examined in a canine model of atrial flutter (cycle length 120 +/- 4 to 131 +/- 3 ms) caused by reentry." | 3.68 | Effects of antiarrhythmic drugs on canine atrial flutter due to reentry: role of prolongation of refractory period and depression of conduction to excitable gap. ( Inoue, H; Nozaki, A; Sugimoto, T; Yamashita, T, 1991) |
| "We describe a case of dangerous acceleration of conduction through an accessory pathway produced by the Class IC agent propafenone during routine electrophysiological study of a patient with Wolff-Parkinson-White syndrome." | 3.68 | Acceleration of conduction within an accessory pathway with propafenone. ( Holt, P; Sowton, GE; Sulke, AN, 1990) |
| "One hundred nine patients with recurrent episodes of symptomatic atrial fibrillation or flutter, or both, who had failed one to five previous antiarrhythmic drug trials were treated with propafenone and, subsequently, sotalol if atrial fibrillation recurred." | 3.68 | Therapy of refractory symptomatic atrial fibrillation and atrial flutter: a staged care approach with new antiarrhythmic drugs. ( Antman, EM; Beamer, AD; Cantillon, C; Friedman, PL; McGowan, N, 1990) |
| "Sixty patients who had recurrent episodes of symptomatic atrial fibrillation or flutter, or both, and who had failed one to five prior drug trials were treated with open label oral propafenone hydrochloride." | 3.67 | Long-term oral propafenone therapy for suppression of refractory symptomatic atrial fibrillation and atrial flutter. ( Antman, EM; Beamer, AD; Cantillon, C; Friedman, PL; Goldman, L; McGowan, N, 1988) |
| "The safety and efficacy of intravenous Propafenone, in the treatment of atrial fibrillation (a." | 3.67 | [Fibrillation and atrial flutter. Immediate control and conversion to sinus rhythm with intravenous propafenone]. ( Bianconi, L; Boccadamo, R; Broglia, R; Pappalardo, A; Pistolese, M, 1987) |
| "Forty-seven patients with chronic atrial fibrillation and (or) flutter in whom the clinical picture and the length of arrhythmia indicated that drug-mediated cardioversion should be tried were treated with a combination of lidoflazine and propafenon." | 3.66 | [Combined use of propafenon and lidoflazine in chronic atrial fibrillation and flutter (author's transl)]. ( Beck, OA; Hochrein, H, 1980) |
| "We randomly assigned 294 patients with paroxysmal atrial fibrillation and no history of antiarrhythmic drug use to an initial treatment strategy of either radiofrequency catheter ablation (146 patients) or therapy with class IC or class III antiarrhythmic agents (148 patients)." | 2.77 | Radiofrequency ablation as initial therapy in paroxysmal atrial fibrillation. ( Cosedis Nielsen, J; Englund, A; Hansen, PS; Hartikainen, J; Hindricks, G; Johannessen, A; Kongstad, O; Mortensen, LS; Pehrson, S; Raatikainen, P; Walfridsson, H, 2012) |
| " Despite careful precautions, serious proarrhythmias, the major limiting side effect of dofetilide, still occurred during long-term follow-up." | 2.73 | Observations on the safety and effectiveness of dofetilide in patients with paroxysmal atrial fibrillation and normal left ventricular function. ( Bauman, JL; Kehoe, RF; Leal, S; Mykytsey, A; Razminia, M; Saleem, M; Wang, T; Zheutlin, T, 2007) |
| "Propafenone is an effective drug for preventing supraventricular tachyarrhythmia, but the incidence of side effects during longterm therapy in patients with such arrhythmias has not been adequately reported." | 2.68 | Safety and tolerability of long-term propafenone therapy for supraventricular tachyarrhythmias. The Propafenone Multicenter Study Group. ( Anderson, JL; Podrid, PJ, 1996) |
| "Propafenone, 2 mg/kg was given over 15 min and blood pressure and heart rate were monitored in the following hour." | 2.66 | [Efficacy of propafenone in supraventricular arrhythmias]. ( Ayala, A; Goich, J; Kauffmann, R; Manzur, F; Parra, C, 1989) |
| " With the intravenous administration of the drug in a dosage of 1." | 2.65 | [Propafenon therapy of arrhythmias in infancy and childhood (author's transl)]. ( Eigster, G; Weber, H; Wesselhoeft, H, 1981) |
| "Atrial flutter is most often arising from a macroreentry circuit in the right atrium or around scar tissue in case or previous cardiothoracic surgery." | 2.43 | [Atrial flutter and fibrillation]. ( Scharf, C, 2005) |
| "Electrocardiography (ECG) showed ventricular tachycardia." | 1.35 | A case of myotonic dystrophy presenting with ventricular tachycardia and atrial fibrillation. ( Eroğlu, S; Müderrisoğlu, H; Ozbiçer, S; Ozin, B, 2009) |
| "Oral propafenone was administered and within 6 hours no further arrhythmias or side effects were noted." | 1.30 | Atrial flutter in a pediatric patient in the immediate period after the Fontan procedure: control with oral propafenone. ( Herzberg, GZ; Rossi, AF, 1997) |
| " In this study, we prospectively investigated the effects of AFI ablation and continuation of drug therapy in patients with AF who developed AFI due to long-term administration of class IC antiarrhythmic drugs." | 1.30 | Radiofrequency ablation of atrial flutter due to administration of class IC antiarrhythmic drugs for atrial fibrillation. ( Jung, W; Lewalter, T; Lüderitz, B; Schumacher, B; Vahlhaus, C; Wolpert, C, 1999) |
| " Dosage and serum levels of propafenone did not differ whether the patients were treated successfully or not." | 1.29 | Clinical experience with propafenone for cardiac arrhythmias in the young. ( Bourgeous, M; Heusch, A; Kramer, HH; Krogmann, ON; Rammos, S, 1994) |
| "Propafenone terminated tachyarrhythmias in all patients during or within a few minutes after stopping infusion (mean conversion time: 6." | 1.28 | [Use of propafenone in emergency therapy]. ( Di Ieso, N; Guardascione, A; Liguori, A; Pellegrino, G; Piatto, A; Ruggiero, P; Scarnera, P, 1989) |
| "Propafenone was less effective (mean effect 3." | 1.27 | European experience with the antiarrhythmic efficacy of propafenone for supraventricular and ventricular arrhythmias. ( Assayag, P; Coumel, P; Leclercq, JF, 1984) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 10 (12.99) | 18.7374 |
| 1990's | 37 (48.05) | 18.2507 |
| 2000's | 21 (27.27) | 29.6817 |
| 2010's | 7 (9.09) | 24.3611 |
| 2020's | 2 (2.60) | 2.80 |
| Authors | Studies |
|---|---|
| Gagloeva, DA | 1 |
| Dzaurova, KM | 1 |
| Zelberg, MA | 1 |
| Mironov, NY | 1 |
| Yuricheva, YA | 1 |
| Sokolov, SF | 1 |
| Golitsyn, SP | 1 |
| Przybylski, R | 1 |
| Eberly, LM | 1 |
| Alexander, ME | 1 |
| Bezzerides, VJ | 1 |
| DeWitt, ES | 1 |
| Dionne, A | 1 |
| Mah, DY | 1 |
| Triedman, JK | 1 |
| Walsh, EP | 1 |
| O'Leary, ET | 1 |
| Bergonti, M | 1 |
| Assanelli, E | 1 |
| Agostoni, P | 1 |
| Yu, Z | 1 |
| Xiang, M | 1 |
| Ma, C | 1 |
| Zhang, S | 1 |
| Yang, Y | 2 |
| Konak, M | 1 |
| Alp, H | 1 |
| Tarakçı, N | 1 |
| Baysal, T | 1 |
| Ors, R | 1 |
| Li, X | 1 |
| Zhang, Y | 2 |
| Liu, H | 1 |
| Jiang, H | 1 |
| Ge, H | 1 |
| Jastrzebski, M | 1 |
| Eroğlu, S | 1 |
| Ozin, B | 1 |
| Ozbiçer, S | 1 |
| Müderrisoğlu, H | 1 |
| Tsai, CF | 1 |
| Sia, SK | 1 |
| Lin, MC | 1 |
| Wu, DJ | 1 |
| Ueng, KC | 1 |
| Blecher, GE | 1 |
| Stiell, IG | 1 |
| Rowe, BH | 1 |
| Lang, E | 1 |
| Brison, RJ | 1 |
| Perry, JJ | 1 |
| Clement, CM | 1 |
| Borgundvaag, B | 1 |
| Langhan, T | 1 |
| Magee, K | 1 |
| Stenstrom, R | 1 |
| Birnie, D | 1 |
| Wells, GA | 1 |
| Cosedis Nielsen, J | 1 |
| Johannessen, A | 1 |
| Raatikainen, P | 1 |
| Hindricks, G | 1 |
| Walfridsson, H | 1 |
| Kongstad, O | 1 |
| Pehrson, S | 1 |
| Englund, A | 1 |
| Hartikainen, J | 1 |
| Mortensen, LS | 1 |
| Hansen, PS | 1 |
| Jalil, E | 2 |
| Mensour, B | 2 |
| Vinet, A | 2 |
| Kus, T | 3 |
| Chiladakis, JA | 1 |
| Kalogeropoulos, A | 1 |
| Patsouras, N | 1 |
| Manolis, AS | 1 |
| Hongo, RH | 1 |
| Themistoclakis, S | 2 |
| Raviele, A | 2 |
| Bonso, A | 2 |
| Rossillo, A | 1 |
| Glatter, KA | 1 |
| Scheinman, MM | 1 |
| Bertaglia, E | 2 |
| Zoppo, F | 1 |
| Proclemer, A | 1 |
| Verlato, R | 1 |
| Corò, L | 1 |
| Mantovan, R | 2 |
| Pascotto, P | 2 |
| Varma, N | 1 |
| Gilkeson, RC | 1 |
| Waldo, AL | 1 |
| Sun, JL | 1 |
| Guo, JH | 2 |
| Zhang, N | 1 |
| Zhang, HC | 2 |
| Zhang, P | 1 |
| Fang, Q | 1 |
| Zheng, YA | 1 |
| Sun, YM | 1 |
| Zhu, WQ | 1 |
| Wan, Z | 1 |
| Guo, JX | 1 |
| Ge, JB | 1 |
| Han, SM | 1 |
| Wiesfeld, AC | 1 |
| Ansink, JM | 1 |
| van Veldhuisen, DJ | 1 |
| van Gelder, IC | 1 |
| Stump, GL | 1 |
| Wallace, AA | 1 |
| Regan, CP | 1 |
| Lynch, JJ | 1 |
| Fragakis, N | 1 |
| Papadopoulos, N | 1 |
| Papanastasiou, S | 1 |
| Kozirakis, M | 1 |
| Maligkos, G | 1 |
| Tsaritsaniotis, E | 1 |
| Katsaris, G | 1 |
| Scharf, C | 1 |
| Kehl, HG | 1 |
| Debus, V | 1 |
| Stege, D | 1 |
| Tjan, TD | 1 |
| Vogt, J | 1 |
| Schulze-Bahr, E | 1 |
| Mykytsey, A | 1 |
| Bauman, JL | 1 |
| Razminia, M | 1 |
| Zheutlin, T | 1 |
| Wang, T | 1 |
| Saleem, M | 1 |
| Leal, S | 1 |
| Kehoe, RF | 1 |
| Chutani, S | 1 |
| Imran, N | 1 |
| Grubb, B | 1 |
| Kanjwal, Y | 1 |
| Gmeiner, R | 1 |
| Sterz, H | 1 |
| Beck, OA | 1 |
| Hochrein, H | 1 |
| Weber, H | 1 |
| Eigster, G | 1 |
| Wesselhoeft, H | 1 |
| Coumel, P | 1 |
| Leclercq, JF | 1 |
| Assayag, P | 1 |
| Doni, F | 4 |
| Della Bella, P | 1 |
| Kheir, A | 2 |
| Manfredi, M | 4 |
| Piemonti, C | 4 |
| Staffiere, E | 4 |
| Rimondini, A | 4 |
| Fiorentini, C | 3 |
| Heusch, A | 1 |
| Kramer, HH | 1 |
| Krogmann, ON | 1 |
| Rammos, S | 1 |
| Bourgeous, M | 1 |
| Minutiello, L | 1 |
| Derakhchan, K | 1 |
| Pagé, P | 1 |
| Lambert, C | 1 |
| Fazekas, T | 1 |
| Kiss, J | 1 |
| Pap, I | 1 |
| Rudas, L | 1 |
| Gutiérrez-Larraya, F | 1 |
| Jabón, A | 1 |
| Manz, M | 1 |
| Lüderitz, B | 2 |
| Di Biasi, P | 1 |
| Scrofani, R | 1 |
| Paje, A | 1 |
| Cappiello, E | 1 |
| Mangini, A | 1 |
| Santoli, C | 1 |
| Hancock, EW | 1 |
| Aliot, E | 1 |
| Denjoy, I | 1 |
| Todd, S | 3 |
| Aouate, P | 1 |
| Frank, R | 1 |
| Fontaine, G | 1 |
| Tonet, J | 1 |
| Tageddine, R | 1 |
| Benassar, A | 1 |
| Turlure, A | 1 |
| Jacquemin, M | 1 |
| Laborde, JP | 1 |
| Podrid, PJ | 1 |
| Anderson, JL | 1 |
| Crijns, HJ | 1 |
| Gosselink, AT | 1 |
| Lie, KI | 2 |
| Larbuisson, R | 1 |
| Venneman, I | 1 |
| Stiels, B | 1 |
| Lardoux, H | 1 |
| Maison Blanche, P | 1 |
| Marchand, X | 1 |
| Canler, A | 1 |
| Rouesnel, P | 1 |
| Bleinc, D | 1 |
| Péraudeau, P | 1 |
| Scheck, F | 1 |
| D'Este, D | 1 |
| Zanocco, A | 1 |
| Franceschi, M | 1 |
| Brembilla-Perrot, B | 1 |
| Terrier de la Chaise, A | 1 |
| Jacquemin, L | 1 |
| Beurrier, D | 1 |
| Houplon, P | 1 |
| Louis, P | 1 |
| Danchin, N | 1 |
| Herzberg, GZ | 1 |
| Rossi, AF | 1 |
| Huang, DT | 1 |
| Monahan, KM | 1 |
| Zimetbaum, P | 1 |
| Papageorgiou, P | 1 |
| Epstein, LM | 1 |
| Josephson, ME | 1 |
| Tai, CT | 2 |
| Chen, SA | 2 |
| Feng, AN | 2 |
| Yu, WC | 2 |
| Chen, YJ | 2 |
| Chang, MS | 2 |
| el-Harari, MB | 1 |
| Adams, PC | 1 |
| Rae, AP | 1 |
| Schumacher, B | 1 |
| Jung, W | 1 |
| Lewalter, T | 1 |
| Vahlhaus, C | 1 |
| Wolpert, C | 1 |
| Nabar, A | 2 |
| Rodriguez, LM | 2 |
| Timmermans, C | 2 |
| Smeets, JL | 1 |
| Wellens, HJ | 2 |
| Carrel, T | 1 |
| Meyer, B | 1 |
| Candinas, R | 1 |
| Turina, M | 1 |
| Schmid, ER | 1 |
| Chiang, CE | 1 |
| Lee, SH | 1 |
| Ding, YA | 1 |
| Naccarelli, GV | 1 |
| Dell'Orfano, JT | 1 |
| Wolbrette, DL | 1 |
| Patel, HM | 1 |
| Luck, JC | 1 |
| Wirth, KJ | 1 |
| Knobloch, K | 1 |
| van Mechelen, R | 1 |
| Gillor, A | 1 |
| Korsch, E | 1 |
| Kingma, JH | 2 |
| Suttorp, MJ | 2 |
| Inoue, H | 2 |
| Yamashita, T | 2 |
| Usui, M | 1 |
| Nozaki, A | 2 |
| Saihara, S | 1 |
| Sugimoto, T | 2 |
| Guccione, P | 1 |
| Drago, F | 1 |
| Di Donato, RM | 1 |
| Cicini, MP | 1 |
| Pasquini, L | 1 |
| Marino, B | 1 |
| Marcelletti, C | 1 |
| Ragonese, P | 1 |
| Jessurun, ER | 1 |
| Lie-A-Huen, L | 1 |
| van Hemel, NM | 1 |
| Antman, EM | 2 |
| Beamer, AD | 2 |
| Cantillon, C | 2 |
| McGowan, N | 2 |
| Friedman, PL | 2 |
| Sulke, AN | 1 |
| Holt, P | 1 |
| Sowton, GE | 1 |
| Murdock, CJ | 1 |
| Kyles, AE | 1 |
| Yeung-Lai-Wah, JA | 1 |
| Qi, A | 1 |
| Vorderbrugge, S | 1 |
| Kerr, CR | 1 |
| Kauffmann, R | 1 |
| Goich, J | 1 |
| Parra, C | 1 |
| Ayala, A | 1 |
| Manzur, F | 1 |
| Liguori, A | 1 |
| Pellegrino, G | 1 |
| Di Ieso, N | 1 |
| Piatto, A | 1 |
| Ruggiero, P | 1 |
| Scarnera, P | 1 |
| Guardascione, A | 1 |
| Bianconi, L | 2 |
| Boccadamo, R | 2 |
| Pappalardo, A | 2 |
| Gentili, C | 1 |
| Pistolese, M | 2 |
| Marchlinski, FE | 1 |
| Goldman, L | 1 |
| Broglia, R | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Medical Antiarrhythmic Treatment or Radiofrequency Ablation in Paroxysmal Atrial Fibrillation: A Randomized Prospective Multicentre Study (MANTRA-PAF)[NCT00133211] | Phase 3 | 294 participants (Actual) | Interventional | 2005-09-30 | Completed | ||
| Inhibition of Atrial Fibrillation by Elimination of Transitional Mechanisms[NCT02758002] | 0 participants (Actual) | Interventional | 2016-01-28 | Withdrawn | |||
| Radiofrequency vs Cryoballoon Catheter Ablation for Pulmonary Vein Isolation in Patients With Atrial Fibrillation - Effect on Atrial Fibrillation Burden Assessed by Implantable Cardiac Monitor (RACE-AF Trial)[NCT03805555] | 105 participants (Actual) | Interventional | 2015-06-30 | Completed | |||
| First-line Cryoablation for Early Treatment of Persistent Atrial Fibrillation - a Randomized Study Comparing Early Trigger Isolation Using the Cryoballoon Versus Antiarrhythmic Medication[NCT05939076] | Phase 3 | 220 participants (Anticipated) | Interventional | 2023-08-21 | Not yet recruiting | ||
| Hybrid Ablation Plus Medical Therapy for Persistent Atrial Fibrillation (HYBRID AF)[NCT04190186] | 90 participants (Anticipated) | Interventional | 2020-06-25 | Recruiting | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
6 reviews available for propafenone and Atrial Flutter
| Article | Year |
|---|---|
[Atrial flutter and fibrillation].
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Adult; Aged; Amiodarone; Anti-Arrhythmia | 2005 |
[Tachycardias: considerations in childhood in the 90s].
Topics: Adenosine; Adolescent; Adult; Amiodarone; Atrial Flutter; Child; Child, Preschool; Electrocardiograp | 1993 |
Supraventricular tachycardia and pre-excitation syndromes: pharmacological therapy.
Topics: Ajmaline; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Flutter; Disopyramide; Fle | 1993 |
[Supraventricular tachycardia with wide QRS complexes during Vaughan-Williams class I anti-arrhythmic treatment. Diagnostic and therapeutic implications].
Topics: Adult; Aged; Aged, 80 and over; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Flutter; Drug Th | 1995 |
Placebo-controlled evaluations of propafenone for atrial tachyarrhythmias.
Topics: Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Atrial Fibrillation; Atrial Flutter; Controlled Clinic | 1998 |
Cost-effective management of acute atrial fibrillation: role of rate control, spontaneous conversion, medical and direct current cardioversion, transesophageal echocardiography, and antiembolic therapy.
Topics: Algorithms; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Flutter; Cost-Benefit An | 2000 |
23 trials available for propafenone and Atrial Flutter
| Article | Year |
|---|---|
[Efficacy and safety of ibutilide for conversion of atrial fibrillation/flutter].
Topics: Adolescent; Adult; Aged; Atrial Fibrillation; Atrial Flutter; Female; Humans; Male; Middle Aged; Pro | 2013 |
Radiofrequency ablation as initial therapy in paroxysmal atrial fibrillation.
Topics: Aged; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Flutter; Catheter Ablation; Cost of Illnes | 2012 |
Radiofrequency ablation as initial therapy in paroxysmal atrial fibrillation.
Topics: Aged; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Flutter; Catheter Ablation; Cost of Illnes | 2012 |
Radiofrequency ablation as initial therapy in paroxysmal atrial fibrillation.
Topics: Aged; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Flutter; Catheter Ablation; Cost of Illnes | 2012 |
Radiofrequency ablation as initial therapy in paroxysmal atrial fibrillation.
Topics: Aged; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Flutter; Catheter Ablation; Cost of Illnes | 2012 |
Radiofrequency ablation as initial therapy in paroxysmal atrial fibrillation.
Topics: Aged; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Flutter; Catheter Ablation; Cost of Illnes | 2012 |
Radiofrequency ablation as initial therapy in paroxysmal atrial fibrillation.
Topics: Aged; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Flutter; Catheter Ablation; Cost of Illnes | 2012 |
Radiofrequency ablation as initial therapy in paroxysmal atrial fibrillation.
Topics: Aged; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Flutter; Catheter Ablation; Cost of Illnes | 2012 |
Radiofrequency ablation as initial therapy in paroxysmal atrial fibrillation.
Topics: Aged; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Flutter; Catheter Ablation; Cost of Illnes | 2012 |
Radiofrequency ablation as initial therapy in paroxysmal atrial fibrillation.
Topics: Aged; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Flutter; Catheter Ablation; Cost of Illnes | 2012 |
Radiofrequency ablation as initial therapy in paroxysmal atrial fibrillation.
Topics: Aged; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Flutter; Catheter Ablation; Cost of Illnes | 2012 |
Radiofrequency ablation as initial therapy in paroxysmal atrial fibrillation.
Topics: Aged; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Flutter; Catheter Ablation; Cost of Illnes | 2012 |
Radiofrequency ablation as initial therapy in paroxysmal atrial fibrillation.
Topics: Aged; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Flutter; Catheter Ablation; Cost of Illnes | 2012 |
Radiofrequency ablation as initial therapy in paroxysmal atrial fibrillation.
Topics: Aged; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Flutter; Catheter Ablation; Cost of Illnes | 2012 |
Radiofrequency ablation as initial therapy in paroxysmal atrial fibrillation.
Topics: Aged; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Flutter; Catheter Ablation; Cost of Illnes | 2012 |
Radiofrequency ablation as initial therapy in paroxysmal atrial fibrillation.
Topics: Aged; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Flutter; Catheter Ablation; Cost of Illnes | 2012 |
Radiofrequency ablation as initial therapy in paroxysmal atrial fibrillation.
Topics: Aged; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Flutter; Catheter Ablation; Cost of Illnes | 2012 |
Ibutilide added to propafenone for the conversion of atrial fibrillation and atrial flutter.
Topics: Administration, Oral; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Flutter; Drug Administrati | 2004 |
Use of ibutilide in cardioversion of patients with atrial fibrillation or atrial flutter treated with class IC agents.
Topics: Aged; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Flutter; Drug Administration Schedule; Dru | 2004 |
Clinical comparison of ibutilide and propafenone for converting atrial flutter.
Topics: Adult; Aged; Anti-Arrhythmia Agents; Atrial Flutter; Dose-Response Relationship, Drug; Double-Blind | 2005 |
[Immediate cardioversion of atrial fibrillation and atrial flutter lasting less than 90 days by ibutilide versus propafenone: a multicenter study].
Topics: Adolescent; Adult; Aged; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Flutter; Electrocardiog | 2005 |
Observations on the safety and effectiveness of dofetilide in patients with paroxysmal atrial fibrillation and normal left ventricular function.
Topics: Adult; Aged; Aged, 80 and over; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Flut | 2007 |
[Propafenon therapy of arrhythmias in infancy and childhood (author's transl)].
Topics: Adolescent; Age Factors; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Atrial Flutter; Atrioventricu | 1981 |
Atrial flutter termination by overdrive transesophageal pacing and the facilitating effect of oral propafenone.
Topics: Administration, Oral; Anti-Arrhythmia Agents; Atrial Flutter; Cardiac Pacing, Artificial; Electrocar | 1995 |
Intravenous amiodarone vs propafenone for atrial fibrillation and flutter after cardiac operation.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Flutter; Coronary Disease; Dos | 1995 |
Comparison of the safety and efficacy of flecainide versus propafenone in hospital out-patients with symptomatic paroxysmal atrial fibrillation/flutter. The Flecainide AF French Study Group.
Topics: Adult; Aged; Ambulatory Care; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Flutter; Female; F | 1996 |
[Facilitating effect of propafenone pretreatment in the interruption of atrial flutter by transesophageal pacing].
Topics: Adult; Aged; Anti-Arrhythmia Agents; Atrial Flutter; Cardiac Pacing, Artificial; Esophagus; Female; | 1996 |
Safety and tolerability of long-term propafenone therapy for supraventricular tachyarrhythmias. The Propafenone Multicenter Study Group.
Topics: Administration, Oral; Adult; Age Factors; Aged; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial | 1996 |
Propafenone versus disopyramide for maintenance of sinus rhythm after electrical cardioversion of chronic atrial fibrillation: a randomized, double-blind study. PRODIS Study Group.
Topics: Aged; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Flutter; Chronic Disease; Disopyramide; Do | 1996 |
The efficacy and safety of intravenous propafenone versus intravenous amiodarone in the conversion of atrial fibrillation or flutter after cardiac surgery.
Topics: Adolescent; Adult; Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Flutter; Fe | 1996 |
Type II atrial flutter interruption with transesophageal pacing: use of propafenone and possible change of the substrate.
Topics: Administration, Oral; Adult; Aged; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Flutter; Atri | 1996 |
[Cibenzoline versus propafenone by the oral route for preventing recurrence of atrial arrhythmia: multicenter, randomized, double-blind study].
Topics: Administration, Oral; Adult; Aged; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Atrial Fibrillation | 1996 |
Efficacy of intravenous propafenone in termination of atrial flutter by overdrive transesophageal pacing previously ineffective.
Topics: Aged; Anti-Arrhythmia Agents; Atrial Flutter; Electric Countershock; Heart Rate; Humans; Middle Aged | 1997 |
New onset atrial flutter termination by overdrive transoesophageal pacing: effects of different protocols of stimulation.
Topics: Administration, Oral; Adult; Aged; Anti-Arrhythmia Agents; Atrial Flutter; Cardiac Pacing, Artificia | 2000 |
Acute pharmacologic conversion of atrial fibrillation and flutter: the role of flecainide, propafenone, and verapamil.
Topics: Atrial Fibrillation; Atrial Flutter; Drug Evaluation; Female; Flecainide; Humans; Male; Middle Aged; | 1992 |
The value of class IC antiarrhythmic drugs for acute conversion of paroxysmal atrial fibrillation or flutter to sinus rhythm.
Topics: Atrial Fibrillation; Atrial Flutter; Electrocardiography; Female; Flecainide; Humans; Male; Middle A | 1990 |
[Efficacy of propafenone in supraventricular arrhythmias].
Topics: Adult; Aged; Atrial Fibrillation; Atrial Flutter; Blood Pressure; Electrocardiography; Female; Heart | 1989 |
Effectiveness of intravenous propafenone for conversion of atrial fibrillation and flutter of recent onset.
Topics: Adult; Aged; Aged, 80 and over; Atrial Fibrillation; Atrial Flutter; Clinical Trials as Topic; Elect | 1989 |
48 other studies available for propafenone and Atrial Flutter
| Article | Year |
|---|---|
Early initiation of anti-relapse antiarrhythmic therapy in patients with atrial fibrillation and flutter after pharmacological cardioversion with refralon.
Topics: Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Flutter; Electric Countershock; Humans; Long QT | 2023 |
Medical cardioversion of atrial fibrillation and flutter with class IC antiarrhythmic drugs in young patients with and without congenital heart disease.
Topics: Adolescent; Adult; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Flutter; Electric Countershoc | 2023 |
The Wrong Drug That Led to the Right Diagnosis.
Topics: Action Potentials; Aged, 80 and over; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Flutter; D | 2019 |
Successful treatment of atrial flutter with propafenone and synchronized cardioversion in a newborn.
Topics: Atrial Flutter; Electric Countershock; Humans; Infant, Newborn; Propafenone | 2014 |
Efficacy of Intravenous Sotalol for Treatment of Incessant Tachyarrhythmias in Children.
Topics: Adolescent; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Flutter; Child; Child, Preschool; Dr | 2017 |
[Proarrhythmic effect of propafenone in patients with atrial fibrillation and atrial flutter].
Topics: Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Atrial Fibrillation; Atrial Flutter; Bundle-Branch Blo | 2008 |
A case of myotonic dystrophy presenting with ventricular tachycardia and atrial fibrillation.
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Flutter; Defibrillators, Implantable | 2009 |
Unstable wide complex tachycardia during propafenone therapy.
Topics: Aged; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Flutter; Electrocardiography; Female; Hear | 2010 |
Use of rate control medication before cardioversion of recent-onset atrial fibrillation or flutter in the emergency department is associated with reduced success rates.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; | 2012 |
Excitable gap composition in the presence of antiarrhythmic drugs in common human atrial flutter.
Topics: Adult; Aged; Aged, 80 and over; Amiodarone; Anti-Arrhythmia Agents; Atrial Flutter; Female; Heart Co | 2003 |
Different clinical courses and predictors of atrial fibrillation occurrence after transisthmic ablation in patients with preablation lone atrial flutter, coexistent atrial fibrillation, and drug induced atrial flutter.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Flutter; Catheter Ablation; Co | 2004 |
Typical counterclockwise atrial flutter occurring despite absence of the inferior vena cava.
Topics: Aged; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Flutter; Catheter Ablation; Electrophysiol | 2004 |
Broad complex tachycardia during treatment of atrial fibrillation with a 1c antiarrhythmic drug: ventricular or supraventricular proarrhythmia?
Topics: Adrenergic beta-Antagonists; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Flutter; Drug Thera | 2006 |
In vivo antiarrhythmic and cardiac electrophysiologic effects of a novel diphenylphosphine oxide IKur blocker (2-isopropyl-5-methylcyclohexyl) diphenylphosphine oxide.
Topics: Animals; Anti-Arrhythmia Agents; Atrial Flutter; Atrial Function; Dogs; Electrocardiography; Electro | 2005 |
Efficacy and safety of ibutilide for cardioversion of atrial flutter and fibrillation in patients receiving amiodarone or propafenone.
Topics: Adult; Aged; Amiodarone; Analysis of Variance; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial F | 2005 |
[Atrial flutter after orthotopic heart transplantation due to recipient-to-donor transatrial conduction].
Topics: Adolescent; Anti-Arrhythmia Agents; Atrial Flutter; Combined Modality Therapy; Electric Countershock | 2005 |
Propafenone-induced Brugada-like ECG changes mistaken as acute myocardial infarction.
Topics: Aged; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Flutter; Brugada Syndrome; Catheter Ablati | 2008 |
[Conservative therapy of supraventricular tachycardias].
Topics: Adrenergic beta-Antagonists; Ajmaline; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Flutter; | 1984 |
[Combined use of propafenon and lidoflazine in chronic atrial fibrillation and flutter (author's transl)].
Topics: Atrial Fibrillation; Atrial Flutter; Cardiac Complexes, Premature; Chronic Disease; Drug Therapy, Co | 1980 |
European experience with the antiarrhythmic efficacy of propafenone for supraventricular and ventricular arrhythmias.
Topics: Adolescent; Adult; Aged; Amiodarone; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Atrial Fibrillati | 1984 |
Clinical experience with propafenone for cardiac arrhythmias in the young.
Topics: Administration, Oral; Adolescent; Arrhythmias, Cardiac; Atrial Flutter; Cardiac Complexes, Premature | 1994 |
[Efficacy of intravenous propafenone in the management of arterial flutter and fibrillation of recent onset].
Topics: Adult; Aged; Aged, 80 and over; Atrial Fibrillation; Atrial Flutter; Echocardiography; Female; Human | 1994 |
Effects of procainamide and propafenone on the composition of the excitable gap in canine atrial reentry tachycardia.
Topics: Action Potentials; Anesthesia; Animals; Atrial Flutter; Atrial Function; Chloralose; Diastole; Disea | 1994 |
[Persistent atrial flutter induced by propafenone (Rytmonorm)].
Topics: Aged; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Flutter; Female; Humans; Propafenone | 1994 |
Atrial flutter in a man with mediastinal cancer.
Topics: Anti-Arrhythmia Agents; Atrial Flutter; Electrocardiography; Humans; Male; Mediastinal Neoplasms; Mi | 1996 |
[Can 1/1 atrial flutter be foreseen by class I anti-arrhythmics?].
Topics: Aged; Anti-Arrhythmia Agents; Atrial Flutter; Disopyramide; Electrocardiography; Female; Flecainide; | 1997 |
Atrial flutter in a pediatric patient in the immediate period after the Fontan procedure: control with oral propafenone.
Topics: Administration, Oral; Anti-Arrhythmia Agents; Atrial Flutter; Child, Preschool; Electrocardiography; | 1997 |
Hybrid pharmacologic and ablative therapy: a novel and effective approach for the management of atrial fibrillation.
Topics: Adult; Aged; Aged, 80 and over; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Flut | 1998 |
Electropharmacologic effects of class I and class III antiarrhythmia drugs on typical atrial flutter: insights into the mechanism of termination.
Topics: Adult; Aged; Amiodarone; Analysis of Variance; Anti-Arrhythmia Agents; Atrial Flutter; Atrial Functi | 1998 |
Atrial flutter with 1:1 atrioventricular conduction caused by propafenone.
Topics: Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Flutter; Atrioventricular Node; Coronary Artery | 1998 |
Radiofrequency ablation of atrial flutter due to administration of class IC antiarrhythmic drugs for atrial fibrillation.
Topics: Administration, Oral; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Flutter; Catheter Ablation | 1999 |
Radiofrequency ablation of "class IC atrial flutter" in patients with resistant atrial fibrillation.
Topics: Administration, Oral; Adult; Aged; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Flutter; Cath | 1999 |
Intravenous amiodarone versus propafenone for atrial fibrillation and flutter after cardiac surgery: a note of caution.
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Flutter; Cardiac Surgical Procedures | 1996 |
Persistent atrial flutter in patients treated for atrial fibrillation with amiodarone and propafenone: electrophysiologic characteristics, radiofrequency catheter ablation, and risk prediction.
Topics: Aged; Aged, 80 and over; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Flutter; El | 1999 |
Influence of propafenone on resetting and termination of canine atrial flutter.
Topics: Action Potentials; Animals; Anti-Arrhythmia Agents; Atrial Flutter; Blood Pressure; Cardiac Pacing, | 2000 |
Differential effects of dofetilide, amiodarone, and class lc drugs on left and right atrial refractoriness and left atrial vulnerability in pigs.
Topics: Amiodarone; Animals; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Flutter; Atrial Function, L | 2001 |
Class IC antiarrhythmic drug induced atrial flutter: electrocardiographic and electrophysiological findings and their importance for long term outcome after right atrial isthmus ablation.
Topics: Adult; Aged; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Flutter; Catheter Ablation; Electro | 2001 |
[Familial manifestation of idiopathic atrial flutter].
Topics: Adolescent; Atrial Fibrillation; Atrial Flutter; Cardiac Complexes, Premature; Child; Digoxin; Drug | 1992 |
Effects of pentisomide and E-4031 on canine atrial flutter due to reentry: a comparative study with disopyramide and propafenone.
Topics: Animals; Anti-Arrhythmia Agents; Atrial Flutter; Disopyramide; Dogs; Electrocardiography; Electrophy | 1991 |
Effects of antiarrhythmic drugs on canine atrial flutter due to reentry: role of prolongation of refractory period and depression of conduction to excitable gap.
Topics: Animals; Anti-Arrhythmia Agents; Atrial Flutter; Cardiac Pacing, Artificial; Disopyramide; Dogs; Ele | 1991 |
Oral propafenone therapy for children with arrhythmias: efficacy and adverse effects in midterm follow-up.
Topics: Administration, Oral; Adolescent; Arrhythmias, Cardiac; Atrial Flutter; Chi-Square Distribution; Chi | 1991 |
Therapy of refractory symptomatic atrial fibrillation and atrial flutter: a staged care approach with new antiarrhythmic drugs.
Topics: Adult; Aged; Atrial Fibrillation; Atrial Flutter; Data Interpretation, Statistical; Drug Administrat | 1990 |
Acceleration of conduction within an accessory pathway with propafenone.
Topics: Adult; Atrial Fibrillation; Atrial Flutter; Cardiac Pacing, Artificial; Electrocardiography; Electro | 1990 |
Atrial flutter in patients treated for atrial fibrillation with propafenone.
Topics: Atrial Fibrillation; Atrial Flutter; Electrocardiography; Follow-Up Studies; Heart Rate; Humans; Pro | 1990 |
[Use of propafenone in emergency therapy].
Topics: Adult; Arrhythmias, Cardiac; Atrial Fibrillation; Atrial Flutter; Drug Evaluation; Electrocardiograp | 1989 |
Propafenone: new therapy for a tough, old arrhythmia.
Topics: Atrial Fibrillation; Atrial Flutter; Electric Countershock; Humans; Propafenone; Recurrence | 1988 |
Long-term oral propafenone therapy for suppression of refractory symptomatic atrial fibrillation and atrial flutter.
Topics: Actuarial Analysis; Administration, Oral; Atrial Fibrillation; Atrial Flutter; Female; Humans; Male; | 1988 |
[Fibrillation and atrial flutter. Immediate control and conversion to sinus rhythm with intravenous propafenone].
Topics: Adult; Aged; Aged, 80 and over; Atrial Fibrillation; Atrial Flutter; Female; Humans; Hypotension; In | 1987 |